Tech companies are building data centers as quickly as possible to run AI. These facilities are controviersial because they use copious amounts of electricity and might tax an electrical grid that in ...

Micron is a leading maker of computer memory products that are vital to the efficient operation of AI data center servers. Its revenue, net income, and free cash flow are growing at incredible rates ...

Organizations have a wealth of unstructured data that most AI models can’t yet read. Preparing and contextualizing this data is essential for moving from AI experiments to measurable results. In ...

A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu.

Licorice extract inhibits tyrosinase production to effectively minimize dark spots and even out skin tone. It's safe to use licorice extract up to twice daily, though it may irritate sensitive skin.

An ambitious data-center project in Utah is going to need about one-quarter of the power the entire state currently uses. David Gray, co-chief executive for the project’s developer, knows he can’t get ...

Two companies at the center of the artificial-intelligence data center investment boom are parting ways, according to a report from the Financial Times. Oracle and alternative investments firm, Blue ...

As many market participants anticipate a year-end rally, there are mounting indications that such an outcome is far from assured. Investor positioning appears increasingly stretched, with multiple ...

BEND, Ore. (KTVZ) -- A data breach has prompted the precautionary closure of all Deschutes Public Library locations through the weekend, but library officials say they are confident no patrons' ...

Snowflake (NYSE:SNOW) shares have surged by nearly 50% this year, although the stock fell on Thursday after the Q3 results were announced. Investors seem to be worried as product revenue growth slowed ...

Almost exactly one year ago, Janux Therapeutics unveiled early data for its investigational T-cell engager that wowed investors and analysts alike. But the biotech’s newest update has failed to garner ...